Overview: Discusses the most recent developments in targeted therapy in hematology using small molecules.Describes chemical structure, mechanism of action, drug targets, and drug interactions.Examines preclinic.This book, written by respected experts, discusses in detail the latest developments in targeted therapy for hematologic malignancies using small molecules. It covers a wide range of small molecules including tyrosine kinase inhibitors, immunomodulatory drugs, the IDH-2 inhibitor enasidenib, the BCL-2 inhibitor venetoclax, and the proteasome inhibitor carfilzomib. For each molecule, asp
|